In part 1 of a two-part podcast, Dr Mease reviews the findings of two clinical trials of the TYK 2 inhibitor deucravacitinib: POETYK 1 of patients without previous biologic treatment, POETYK 2, which included some patients with exposure to...
In part 1 of a two-part podcast, Dr Mease reviews the findings of two clinical trials of the TYK 2 inhibitor deucravacitinib: POETYK 1 of patients without previous biologic treatment, POETYK 2, which included some patients with exposure to...
In part 2 of her video on psoriatic arthritis and obesity, Dr Ogdie reviews recent studies showing how combination therapy with GLP-1 RAs may not only boost weight loss but also help patients achieve minimal disease activity.
In part 2 of her video on psoriatic arthritis and obesity, Dr Ogdie reviews recent studies showing how combination therapy with GLP-1 RAs may not only boost weight loss but also help patients achieve minimal disease activity.
In the first of two videos on the impact and treatment of obesity in psoriatic arthritis, Dr Alexis Ogdie reviews recent research on how obesity affects the severity of disease and the effect of weight loss on patients with PsA.
In the first of two videos on the impact and treatment of obesity in psoriatic arthritis, Dr Alexis Ogdie reviews recent research on how obesity affects the severity of disease and the effect of weight loss on patients with PsA.
Key predictors of demyelinating disease development included a diagnosis of axial spondyloarthritis, presence of inflammatory bowel disease, and a history of smoking.
Key predictors of demyelinating disease development included a diagnosis of axial spondyloarthritis, presence of inflammatory bowel disease, and a history of smoking.
A recent study found no significant difference in the risk of cardiovascular events among rheumatoid arthritis patients treated with Janus kinase inhibitors or biologic disease-modifying drugs.
A recent study found no significant difference in the risk of cardiovascular events among rheumatoid arthritis patients treated with Janus kinase inhibitors or biologic disease-modifying drugs.
